Vascular endothelial dysfunction in β-Thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NO

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Stoyanova, Ekatherina ^a,b   Trudel, Marie ^b   Felfly, Hady ^b   Lemsaddek, Wafaa ^b   Garcia, Damien ^a   Cloutier, Guy ^a,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ELASTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL WALL; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; EX VIVO STUDY; MALE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; THALASSEMIA MAJOR; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION; WALL STRESS; WESTERN BLOTTING;

ACETYLCHOLINE; ANIMALS; BETA-THALASSEMIA; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; VASCULAR RESISTANCE; VASODILATOR AGENTS; VASOMOTOR SYSTEM;

EID: 84862568042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038089     Document Type: Article

References (35)

1. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, et al. (2005) Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 127: 1523-30.
2. Modell B, Khan M, Darlison M, (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355: 2051-2.
3. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, et al. (2004) Cardiac status in well-treated patients with thalassemia major. European Journal of Haematology 73: 359-66.
4. Panigrahi I, Agarwal S, (2007) Thromboembolic complications in [beta]-thalassemia: beyond the horizon. Thrombosis Research 120: 783-9.
5. Eldor A, Rachmilewitz EA, (2002) The hypercoagulable state in thalassemia. Blood 99: 36-43.
6. Chen S, Eldor A, Barshtein G, Zhang S, Goldfarb A, et al. (1996) Enhanced aggregability of red blood cells of beta-thalassemia major patients. American Journal of Physiology 270: H1951-6.
7. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G, (1999) Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. British Journal of Haematology 106: 178-81.
8. Kyriakou DS, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, et al. (2001) Activated peripheral blood and endothelial cells in thalassemia patients. Annals of Hematology 80: 577-83.
9. Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, et al. (2002) Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. American Journal of Hematology 70: 100-6.
10. Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, et al. (2008) Global vasomotor dysfunction and accelerated vascular aging in [beta]-thalassemia major. Atherosclerosis 198: 448-57.
11. Cheung YF, Chan GC, Ha SY, (2002) Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 106: 2561-6.
12. Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, et al. (2009) Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. European Journal of Haematology 82: 477-83.
13. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, et al. (1998) Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. Journal of Clinical Investigation 101: 731-6.
14. Gedikli O, Altinbas A, Orucoglu A, Dogan A, Ozaydin M, et al. (2007) Elastic properties of the ascending aorta in patients with beta-thalassemia major. Echocardiography 24: 830-6.
15. Stakos DA, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, et al. (2009) Cardiovascular involvement in patients with [beta]-thalassemia major without cardiac iron overload. International Journal of Cardiology 134: 207-11.
16. Stoyanova E, Trudel M, Felfly H, Garcia D, Cloutier G, (2007) Characterization of circulatory disorders in beta-thalassemic mice by noninvasive ultrasound biomicroscopy. Physiological Genomics 29: 84-90.
17. Skow LC, Burkhart BA, Johnson FM, Popp RA, Popp DM, et al. (1983) A mouse model for beta-thalassemia. Cell 34: 1043-52.
18. Schiffrin EL, Hayoz D, (1997) How to assess vascular remodelling in small and medium-sized muscular arteries in humans. Journal of Hypertension 15: 571-84.
19. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC, (2005) Heart failure in beta-thalassemia syndromes: a decade of progress. American Journal of Medicine 118: 957-67.
20. Morris CR, (2008) Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program pp. 177-85.
21. Gladwin MT, Lancaster JR, Freeman BA, Schechter AN, (2003) Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nature Medicine 9: 496-500.
22. Minneci PC, Deans KJ, Zhi H, Yuen PS, Star RA, et al. (2005) Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. Journal of Clinical Investigation 115: 3409-17.
23. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, et al. (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA: Journal of the American Medical Association 294: 81-90.
24. Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, et al. (2003) Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clinica Chimica Acta 338: 79-86.
25. Gladwin MT, Kato GJ, (2005) Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program pp. 51-7.
26. Frei AC, Guo Y, Jones DW, Pritchard KA Jr, Fagan KA, et al. (2008) Vascular dysfunction in a murine model of severe hemolysis. Blood 112: 398-405.
27. Rother RP, Bell L, Hillmen P, Gladwin MT, (2005) The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA: Journal of the American Medical Association 293: 1653-62.
28. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, et al. (2007) Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109: 3088-98.
29. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL, (1996) Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proceedings of the National Academy of Sciences of the United States of America 93: 6770-4.
30. Aggeli CJ, Antoniades C, Cosma C, Chrysohoou C, Tousoulis D, et al. (2005) Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. International Journal of Cardiology 105: 80-4.
31. Cheung YF, Chow PC, Chan GC, Ha SY, (2006) Carotid intima-media thickness is increased and related to arterial stiffening in patients with beta-thalassaemia major. British Journal of Haematology 135: 732-4.
32. Ulger Z, Aydinok Y, Gurses D, Levent E, Ozyurek AR, (2006) Stiffness of the abdominal aorta in beta-thalassemia major patients related with body iron load. Journal of Pediatric Hematology/Oncology 28: 647-52.
33. Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, et al. (2003) Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation 107: 2601-6.
34. Faller DV, (1999) Endothelial cell responses to hypoxic stress. Clinical and Experimental Pharmacology and Physiology 26: 74-84.
35. Fortuno A, Jose GS, Moreno MU, Diez J, Zalba G, (2005) Oxidative stress and vascular remodelling. Experimental Physiology 90: 457-62.